haloperidol has been researched along with Atrioventricular Block in 2 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Atrioventricular Block: Impaired impulse conduction from HEART ATRIA to HEART VENTRICLES. AV block can mean delayed or completely blocked impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram." | 7.85 | Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram." | 3.85 | Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Kambayashi, R | 1 |
| Izumi-Nakaseko, H | 2 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Kanda, Y | 1 |
| Sugiyama, A | 2 |
| Nakamura, Y | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Ando, K | 1 |
2 other studies available for haloperidol and Atrioventricular Block
| Article | Year |
|---|---|
Validation of Risk-Stratification Method for the Chronic Atrioventricular Block Cynomolgus Monkey Model and Its Mechanistic Interpretation Using 6 Drugs With Pharmacologically Distinct Profile.
Topics: Animals; Astemizole; Atrioventricular Block; DNA-Binding Proteins; Electrocardiography; Haloperidol; | 2022 |
Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
Topics: Animals; Antipsychotic Agents; Atrioventricular Block; Chronic Disease; Dogs; Electrocardiography; F | 2017 |